Lexaria Bioscience (LEXX) Convertible Debt (2016 - 2017)
Lexaria Bioscience's (LEXX) quarterly Convertible Debt came in at $45000.0 in Q2 2017, little changed year-on-year from $45000.0 in Q2 2016, and little changed quarter-over-quarter from $45000.0 in Q1 2017.
Lexaria Bioscience (LEXX) Convertible Debt (2016 - 2017) Analysis & Trends
Lexaria Bioscience has disclosed Convertible Debt across 2 years of filings, most recently posting $45000.0 for Q2 2017.
- Convertible Debt for Q2 2017 came in at $45000.0, changed 0.0% year-over-year; the trailing twelve-month figure through May 2017 was $45000.0 (changed 0.0% YoY), and the FY2016 annual result was $45000.0, changed N/A from the prior year.
- Convertible Debt came in at $45000.0 for Q2 2017 at Lexaria Bioscience, roughly flat from $45000.0 in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $45000.0 in Q2 2016 to a low of $45000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2017 | 45,000.00 |
| Feb 28, 2017 | 45,000.00 |
| Nov 30, 2016 | 45,000.00 |
| Aug 31, 2016 | 45,000.00 |
| May 31, 2016 | 45,000.00 |